Paul Tudor Jones's RAPP Position Overview
Paul Tudor Jones (via Tudor Investment Corp Et Al) currently holds 11,149 shares of Rapport Therapeutics, Inc. (RAPP) worth $331,125, representing 0.00% of the portfolio. First purchased in 2025-Q3, this recently established position has been held for 1 quarters.
Based on recent 13F filings, Paul Tudor Jones has initiated a new position in RAPP, representing a fresh investment thesis on this company. Insufficient history to summarize additions or reductions.
Analysis based on 13F filings available since 2013 Q2
Paul Tudor Jones's Rapport Therapeutics (RAPP) Holding Value Over Time
Track share changes against reported price movement
Quarterly Rapport Therapeutics (RAPP) Trades by Paul Tudor Jones
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q3 2025 | +11,149 | New Buy | 11,149 | $29.70 |
Paul Tudor Jones's Rapport Therapeutics Investment FAQs
Paul Tudor Jones first purchased Rapport Therapeutics, Inc. (RAPP) in Q3 2025, acquiring 11,149 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Paul Tudor Jones has held Rapport Therapeutics, Inc. (RAPP) for 1 quarters since Q3 2025.
Paul Tudor Jones's largest addition to Rapport Therapeutics, Inc. (RAPP) was in Q3 2025, adding 11,149 shares worth $331,125.
According to the latest 13F filing for Q3 2025, Paul Tudor Jones's firm, Tudor Investment Corp Et Al, owns 11,149 shares of Rapport Therapeutics, Inc. (RAPP), valued at approximately $331,125.
As of the Q3 2025 filing, Rapport Therapeutics, Inc. (RAPP) represents approximately 0.00% of Paul Tudor Jones's publicly disclosed stock portfolio, making it one of their key holdings.
Paul Tudor Jones's peak holding in Rapport Therapeutics, Inc. (RAPP) was 11,149 shares, as reported at the end of Q3 2025.